SET-171
SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 μM and 2.97 μM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD) -related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD[1].
Product Specifications
CAS Number
3052985-32-4
UNSPSC
12352005
Target
JNK; Pyruvate Kinase
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Metabolic Enzyme/Protease
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/set-171.html
Smiles
BrC1=CC=CC(NC(CN2CCC3=C(SC(NC(C4=CC=CC5=C4C=CC=C5)=O)=C3C#N)C2)=O)=C1
Molecular Formula
C27H21BrN4O2S
Molecular Weight
545.45
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human SF3B4 shRNA (UAS) - Lentiviral human SF3B4 shRNA (UAS, iRFP) (25)
